Posted by Michael Wonder on 03 Mar 2017
The scandal of generic drug pricing: drug regulation policies need review
23 February 2017 - We welcome the news that the Competitions and Market Authority is now taking drug companies such as GlaxoSmithKline, Pfizer, and Flynn Pharma to task for overcharging the NHS for generic drugs.
In December, the authority announced that it was investigating Actavis for inflating the price of hydrocortisone, a WHO essential medicine used to treat adrenal insufficiency.
